Search PubMed⌕ Search

PubMed · 6304252

The nerve growth factor receptor on PC12 cells: interconversion between two forms with different binding properties.

Abstract

PC12 cells possess two classes of nerve growth factor (NGF) receptors on their surfaces which can be distinguished by kinetic criteria. The majority class binds and releases 125I-NGF at a relatively rapid rate and has been called fast. The second class of receptors has been called slow because of relatively slower rates of binding and release of 125I-NGF, and also may be distinguished from fast receptors by their cytoskeletal association and resistance to trypsin. PC12 cell plasma membranes were prepared and shown to have only the fast class of receptors. These membranes were fused to receptorless 3T3 cells with polyethylene glycol. The resultant fused cells were shown to possess NGF receptors, essentially all of which behave like slow receptors. Immunofluorescence microscopy was used to monitor the introduction of PC12 cell membrane and NGF receptors into 3T3 cells. Results obtained with C10-2, a monoclonal antibody specific for a major PC12 cell-surface antigen. show that up to 90% of 3T3 cells receive PC12 membrane and that the PC12 membrane becomes integrally incorporated into the 3T3 cell plasma membrane. It is suggested that an association of receptors with cytoskeleton may be involved in the conversion of fast to slow receptor behavior, and that the differing proportion of fast and slow NGF receptors in PC12 and 3T3 cells reflects the differing cytoskeletal organization of these cells.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

T Block, M Bothwell. 1983. The nerve growth factor receptor on PC12 cells: interconversion between two forms with different binding properties.. https://doi.org/10.1111/j.1471-4159.1983.tb08139.x

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Treatment of neuroblastoma-related opsoclonus-myoclonus-ataxia syndrome with high-dose dexamethasone pulses.

Opsoclonus-myoclonus-ataxia-syndrome (OMS) represents a rare neuroblastoma-associated paraneoplastic syndrome that commonly results in neurologic deficits despite tumor resection and immunosuppressive therapy. We describe the response of five such children to high-dose dexamethasone pulses including two patients in whom previous glucocorticoids, rituximab, and cytostatic drugs were not successful. All patients had MYCN non-amplified tumors that were detected 1 to 7 months after the onset of the OMS or ataxia. This treatment resulted in a good partial response in three and in complete remission in two patients. Our results show that dexamethasone pulses are likely to be useful for both, first-line- and salvage-therapy for OMS-patients.

Adrenal Gland Neoplasms↗

Malignant paragangliomas associated with mutations in the succinate dehydrogenase D gene.

INTRODUCTION: Malignant paragangliomas have been well described in carriers of mutations of the succinate dehydrogenase B (SDHB) gene, but have rarely been associated with mutations in the succinate dehydrogenase D (SDHD) gene. AIM: The aim of the study was to report the different clinical expression patterns of malignant paragangliomas in five patients with SDHD (D92Y) mutations observed in approximately 200 SDHD (D92Y) mutation carriers followed in our institution. RESULTS: Metastasis and/or local tumor invasion was documented 0 (n=2), 1, 18, and 30 yr after the initial diagnosis of paraganglioma. Malignancy was proven by paraganglioma bone metastases (n=2), intrathoracic paraganglioma with lymph node metastases, locally invasive head-and-neck paraganglioma with destruction of the petrosal bone, and locally invasive paraganglioma of the bladder with lymph node metastases. Four of the five patients developed catecholamine excess during follow-up due to intraadrenal paraganglioma (pheochromocytoma) (n=1), extra adrenal paraganglioma (n=2), and presumed subclinical disease (n=1). CONCLUSION: SDHD mutations (D92Y) are associated with malignant paragangliomas and catecholamine excess with remarkable interindividual variations despite the same mutation. We estimate that the prevalence of malignancy in carriers of D92Y mutations is at least 2.5%.

Adrenal Gland Neoplasms↗